$TNXP

$TNXPr/pennystocksDDbullish

u/PossibleLack835 · 328d ago1 prior · 0% at 3mo

TNXP is undervalued

Tonmya, the first FDA-approved fibromyalgia drug in 15 years, is projected to generate $49-130M annually with 1% market penetration and $219-365M by late 2026 at higher penetration. TNXP has $190M cash (exceeding market cap), profitability expected next year, and a $35M buyback with 20% short float positioning the stock for significant upside from current depressed levels.

At post $15.97Now $5.43-66.0% since postedas of Oct 21, 4:46 PM ET

1d—

3d—

1w+22.3%

1m+1.8%

3m-7.1%

6m-20.0%

1y—

original post →

$TNXPr/pennystocksDDbullish

u/Derp2638 · 2080d agono track record yet

Long 4,300 shares of TNXP

NASDAQ: $TNXP - Tonix Pharmaceuticals A COVID pennystock with an actual pipeline and potential for 10-15$/ or 500%-1000% gains. AND with Institutions loading up DD

Tonix Pharmaceuticals is a clinical-stage biotech with multiple pipeline candidates addressing large markets: TNX-102 for fibromyalgia (phase 3 positive results, $2.8B market) and Alzheimer's agitation (FDA Fast Track, $3.5B market), TNX-1500 for organ rejection, and TNX-1800 COVID vaccine with T-cell immunity. Recent institutional funding rounds totaling ~$110M have given the company $150M in cash and institutions ~33% ownership, positioning the stock for 10-15x upside as candidates advance.

At post $1,030,400.00Now $5.43-100.0% since postedas of Oct 21, 4:46 PM ET

1d+1.2%

3d+13.0%

1w+9.9%

1m-25.5%

3m-36.0%

6m-57.1%

1y-86.3%

original post →

Recent theses

TNXP is undervalued

NASDAQ: $TNXP - Tonix Pharmaceuticals A COVID pennystock with an actual pipeline and potential for 10-15$/ or 500%-1000% gains. AND with Institutions loading up DD